HOME >> BIOLOGY >> NEWS
Cancer research finds targets for new cholesterol-lowering therapies

(Uppsala, June 7th) -- A team of investigators from the Uppsala Branch of the Ludwig Institute for Cancer Research (LICR) and Harvard Medical School has uncovered novel targets for the development of drugs that would potentially complement, or replace, statins in treating heart disease.

Statins are commonly taken drugs that reduce the levels of low density lipoprotein (LDL) and have been shown to reduce risks associated with heart disease, the number one killer in the Western world. However, statins are not suitable for all patients, and reduce cardiovascular events by only 20%- 40%. Additionally, some genetic causes of high cholesterol cannot be treated with statins.

According to LICR's Dr. Johan Ericsson, the senior author of the study published today in Cell Metabolism, the team found that a protein called Fbw7 degrades the SREBP proteins that drive lipid and cholesterol production. "We found that inhibiting Fbw7 resulted in increased SREBP levels and an enhanced uptake of LDL, so a drug that blocks the interaction between Fbw7 and SREBP proteins would probably enhance the removal of harmful LDL-cholesterol from the circulation. We can only speculate at this stage, but a two-pronged attack on LDL removal, combining a statin with a treatment that prevents Fbw7/SREBP interaction would likely be of more benefit to some patients than statins alone."

Dr. Ericsson said that the team also found that the Fbw7/SREBP interaction may also be connected to diabetes, as insulin signaling inhibited Fbw7's ability to affect SREBP levels and thus increased lipid and cholesterol synthesis. Finally, the Fbw7/SREBP interaction also provides a theoretical link between lipid synthesis and the aberrant growth of cancer cells. The loss of Fbw7, which is inactivated in some breast, endometrial, ovarian and colon cancers, has been shown to make cells multiply faster and synthesize more lipids; factors that are critical for tumor growth. Aspects of both links are u
'"/>

Contact: Sarah L. White, Ph.D.
swhite@licr.org
1-917-974-7952
Ludwig Institute for Cancer Research
7-Jun-2005


Page: 1 2

Related biology news :

1. Journalists can register now for ECCO 14 -- the European Cancer Conference
2. Cancer cures could work for canines and humans
3. The Cancer Genome Atlas awards funds for technology development
4. Cancer research specialist and HSPH professor awarded Medal of Honor from WHO cancer agency
5. Cancer stem cells similar to normal stem cells can thwart anti-cancer agents
6. Cancer stem cells can go it alone
7. Cancer drug enhances long-term memory
8. Cancer cells reprogram energy needs to grow and spread, study suggests
9. Cancer scientists create human leukemia process to map how disease begins, progresses
10. Cancer tip -- Nanoparticles can damage DNA, increase cancer risk
11. Other highlights from the April 18 Journal of the National Cancer Institute

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/10/2018)... ... December 10, 2018 , ... Nanomedical Diagnostics , leading producer ... to 9640 Towne Centre Drive, Suite 100, effectively tripling its space from 5,200 to ... and internationally, for the sales of our drug discovery platforms. We’re in the great ...
(Date:12/5/2018)... ... December 03, 2018 , ... uBiome, the leader in microbial ... the Division of Gastroenterology and Hepatology at UC San Diego and staff gastroenterologist ... the board of leading scientists and doctors from around the world, Dr. Zarrinpar ...
(Date:12/5/2018)... ... December 04, 2018 , ... ... synthesizer, the Dr. Oligo 192c, built on Biolytic’s Molecule Synthesis Platform. , ... allowed them to become the world’s fastest in oligonucleotide synthesis, the 192c incorporates ...
Breaking Biology News(10 mins):
(Date:11/28/2018)... SAN DIEGO, CALIF. (PRWEB) , ... November 28, 2018 , ... ... learn more about Italian cuisine, as well as experience the height of truffle season. ... for its delicious food and pristine countryside. Staying in the exclusive Black Truffle Lodge ...
(Date:11/20/2018)... ... 2018 , ... Each year Forbes receives thousands of nominations for candidates wishing ... by individuals under 30 years of age. The Forbes 30 Under 30 list showcases ... to Venture Capital and Science. , In 2017, Visikol CEO Dr. Michael Johnson ...
(Date:11/13/2018)... ... November 12, 2018 , ... Dr. Dan ... and Sandy Springs, now welcomes new patients for MTM® Clear Aligners. Offering a ... to traditional braces in the Sandy Springs and Alpharetta areas. Constantly on the ...
(Date:11/9/2018)... ... November 08, 2018 , ... uBiome, the leader ... Executive Officer and President of Andes Biotechnologies, to its Scientific Advisory Board. Joining ... brings to uBiome expertise on the genetic studies of hepatitis viruses. The appointment ...
Breaking Biology Technology:
Cached News: